NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that its Medicare administrative carrier Novitas Solutions has issued a new local coverage determination for the company's PancraGen pancreatic cyst cancer risk stratification test.

The new policy, which covers about 55 million individuals, is non-conditional, Interpace noted. Previously, the company was required to send ongoing data to Novitas for analysis for approved continued coverage of the test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.